首页> 外文期刊>Nature >Na~+ controls hypoxic signalling by the mitochondrial respiratory chain
【24h】

Na~+ controls hypoxic signalling by the mitochondrial respiratory chain

机译:Na〜+通过线粒体呼吸链控制缺氧信号

获取原文
获取原文并翻译 | 示例
       

摘要

All metazoans depend on the consumption of O(2)by the mitochondrial oxidative phosphorylation system (OXPHOS) to produce energy. In addition, the OXPHOS uses O(2)to produce reactive oxygen species that can drive cell adaptations(1-4), a phenomenon that occurs in hypoxia(4-8)and whose precise mechanism remains unknown. Ca(2+)is the best known ion that acts as a second messenger(9), yet the role ascribed to Na(+)is to serve as a mere mediator of membrane potential(10). Here we show that Na(+)acts as a second messenger that regulates OXPHOS function and the production of reactive oxygen species by modulating the fluidity of the inner mitochondrial membrane. A conformational shift in mitochondrial complex I during acute hypoxia(11)drives acidification of the matrix and the release of free Ca(2+)from calcium phosphate (CaP) precipitates. The concomitant activation of the mitochondrial Na+/Ca(2+)exchanger promotes the import of Na(+)into the matrix. Na(+)interacts with phospholipids, reducing inner mitochondrial membrane fluidity and the mobility of free ubiquinone between complex II and complex III, but not inside supercomplexes. As a consequence, superoxide is produced at complex III. The inhibition of Na(+)import through the Na+/Ca(2+)exchanger is sufficient to block this pathway, preventing adaptation to hypoxia. These results reveal that Na(+)controls OXPHOS function and redox signalling through an unexpected interaction with phospholipids, with profound consequences for cellular metabolism.Na(+)controls the function of the mitochondrial oxidative phosphorylation system and hypoxic redox signalling through an unexpected interaction with phospholipids.
机译:所有美唑烷均取决于线粒体氧化磷酸化系统(汤膦)的O(2)的消耗以产生能量。此外,毒物使用O(2)产生可以驱动细胞适应(1-4)的反应性氧物质,缺氧(4-8)中发生的现象,其精确机制仍然未知。 Ca(2+)是充当第二信使(9)的最佳已知的离子,但归因于Na(+)的作用是仅用作膜电位(10)的仅介体。在这里,我们表明na(+)作为调节毒物功能和通过调节内线粒体膜的流动性来调节毒物功能和活性氧物质的产生的第二信使。在急性缺氧(11)期间线粒体复合物I的构象变化驱动基质的酸化和来自磷酸钙(帽)沉淀物的游离Ca(2+)的释放。线粒体Na + / Ca(2+)交换剂的伴注激活促进Na(+)进入基质。 Na(+)与磷脂相互作用,减少内部线粒体膜流动性和在复合物II和复合III之间的游离泛醌的迁移率,但不包括在超复杂内。结果,超氧化物在复杂的III中产生。通过Na + / Ca(2+)交换器的Na(+)进口的抑制足以阻断该途径,防止适应缺氧。这些结果表明,Na(+)通过与磷脂的意外相互作用控制毒物功能和氧化还原信号传导,对细胞代谢的深刻后果。通过意外的相互作用控制线粒体氧化磷酸化系统和缺氧氧化还原信号的功能。磷脂。

著录项

  • 来源
    《Nature》 |2020年第7828期|287-291|共5页
  • 作者单位

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain|Ctr Nacl Invest Cardiovasc Carlos III CNIC Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain;

    Basque Res & Technol Alliance BRTA Ctr Cooperat Res Biomat CIC BiomaGUNE Donostia San Sebastian Spain|Ctr Invest Biomed Red Enfermedades Resp CIBERES Madrid Spain;

    Hosp Univ La Princesa Inst Invest Sanitaria Princesa IIS IP Serv Inmunol Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain;

    Hosp Univ La Princesa Inst Invest Sanitaria Princesa IIS IP Serv Inmunol Madrid Spain;

    Ctr Invest Biomed Red Enfermedades Resp CIBERES Madrid Spain|Univ Complutense Madrid UCM Inst Invest Sanitaria Gregorio Maranon IISGM Dept Farmacol & Toxicol Fac Med Madrid Spain;

    Hosp Univ La Princesa Inst Invest Sanitaria Princesa IIS IP Serv Inmunol Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain;

    Univ Pablo de Olavide CSIC Ctr Andaluz Biol Desarrollo Seville Spain|Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid Spain;

    Ctr Nacl Invest Cardiovasc Carlos III CNIC Madrid Spain;

    Temple Univ Lewis Katz Sch Med Ctr Translat Med Philadelphia PA 19122 USA;

    Univ Autonoma Madrid UAM Inst Invest Sanitaria Princesa IIS IP Dept Farmacol & Terapeut Fac Med Inst Teofilo Hernando Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain|Univ Autonoma Madrid UAM Inst Invest Sanitaria Princesa IIS IP Dept Farmacol & Terapeut Fac Med Inst Teofilo Hernando Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain|Univ Autonoma Madrid UAM Inst Invest Sanitaria Princesa IIS IP Dept Farmacol & Terapeut Fac Med Inst Teofilo Hernando Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain;

    Ctr Nacl Invest Cardiovasc Carlos III CNIC Madrid Spain|Univ Calif Los Angeles David Geffen Sch Med Dept Med Los Angeles CA 90095 USA|Univ Calif Los Angeles David Geffen Sch Med Dept Mol & Med Pharmacol Los Angeles CA 90095 USA;

    Univ Pablo de Olavide CSIC Ctr Andaluz Biol Desarrollo Seville Spain|Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid Spain;

    Univ Pablo de Olavide CSIC Ctr Andaluz Biol Desarrollo Seville Spain|Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid Spain;

    Univ Complutense Madrid Inst Invest Sanitaria Hosp 12 Octubre Imas12 Dept Quim Fis Madrid Spain;

    Univ Complutense Madrid UCM Dept Bioquim & Biol Mol Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain|Univ Autonoma Madrid UAM Inst Invest Sanitaria Princesa IIS IP Dept Farmacol & Terapeut Fac Med Inst Teofilo Hernando Madrid Spain;

    Univ Autonoma Madrid UAM Inst Invest Sanitaria Princesa IIS IP Dept Farmacol & Terapeut Fac Med Inst Teofilo Hernando Madrid Spain;

    Basque Res & Technol Alliance BRTA Ctr Cooperat Res Biomat CIC BiomaGUNE Donostia San Sebastian Spain|Ctr Invest Biomed Red Enfermedades Resp CIBERES Madrid Spain|Ikerbasque Basque Fdn Sci Bilbao Spain|Univ Complutense Madrid UCMM Fac Farm Dept Quim Ciencias Farmaceut Madrid Spain;

    Univ Zurich Vetsuisse Fac Inst Vet Physiol Red Blood Cell Grp Zurich Switzerland|Univ Zurich ZIHP Zurich Switzerland;

    Ctr Nacl Invest Cardiovasc Carlos III CNIC Madrid Spain|Ctr Invest Biomed Red Fragilidad Envejecimiento S Madrid Spain;

    Hosp Univ Santa Cristina Inst Invest Sanitaria Princesa IIS IP Unidad Invest Madrid Spain|Univ Complutense Madrid UCM Dept Bioquim & Biol Mol Madrid Spain|Ctr Invest Biomed Red Enfermedades Cardiovasc CIB Madrid Spain;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 22:15:29

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号